Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan

International Journal of Molecular Sciences - Switzerland
doi 10.3390/ijms20153801
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

History of Development and Regulations for Regenerative Medicines in Japan

Journal of Stem Cell Research & Therapy
2017English

First Approval of Regenerative Medical Products Under the PMD Act in Japan

Cell Stem Cell
Molecular MedicineGeneticsCell Biology
2016English

Php359 - Impact of Expedited Marketing Authorisation on Pricing and Reimbursement Outcomes for Drugs in the Us and Eu-5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Economic Structure and Interdependence Between Japan, US, EU and Asia Based on "The 1990 Japan-Us-Eu-Asia Input-Output Table"

Input-Output Analysis
1999English

Conditional Approval: Japan Lowers the Bar for Regenerative Medicine Products

Cell Stem Cell
Molecular MedicineGeneticsCell Biology
2015English

Price Comparison of New Drugs in Japan, Eu and Us

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Bringing Regenerative Medicines to the Clinic: The Future for Regulation and Reimbursement

Regenerative Medicine
EmbryologyBiomedical Engineering
2015English

National Medicines Policies – A Review of the Evolution and Development Processes

Journal of Pharmaceutical Policy and Practice
ToxicologyPharmaceuticsPharmacologyHealth Policy
2013English

ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy